Walgreens Boots Alliance (DB:W8A) - Cotización, noticias y análisis

Resumen de acción W8A

Walgreens Boots Alliance, Inc. opera como empresa de asistencia sanitaria, farmacia y venta al por menor en Estados Unidos, Reino Unido, Alemania e internacionalmente.

Acerca de la empresa

W8A fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	0/6
Financial Health	1/6
Dividends	2/6

Recompensas

Cotiza un 71.1% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 24.6%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

El dividendo de 4.48% no está bien cubierto por los beneficios o los flujos de caja

Los pagos de intereses no están bien cubiertos por los beneficios

Competidores de Walgreens Boots Alliance, Inc.

Redcare Pharmacy

XTRA:RDC

€2.6b

Metro

XTRA:B4B

€1.8b

HelloFresh

XTRA:HFG

€1.1b

Raia Drogasil

BOVESPA:RADL3

R$43.6b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Walgreens Boots Alliance
Historical stock prices
Current Share Price	US$16.56
52 Week High	US$32.21
52 Week Low	US$16.47
Beta	0.75
1 Month Change	-13.61%
3 Month Change	-19.55%
1 Year Change	-48.48%
3 Year Change	-62.23%
5 Year Change	-64.79%
Change since IPO	-50.57%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	W8A	DE Consumer Retailing	Mercado DE
7D	-1.9%	-3.3%	-1.7%
1Y	-48.5%	-36.7%	-0.2%

Rentabilidad vs. Industria: W8A obtuvo unos resultados inferiores a los del sector German Consumer Retailing , que el año pasado arrojó un rendimiento del -20.1%.

Rentabilidad vs. Mercado: W8A obtuvo unos resultados inferiores a los del mercado German, que fue del -1.4% el año pasado.

Volatilidad de los precios

Is W8A's price volatile compared to industry and market?
W8A volatility
W8A Average Weekly Movement	5.7%
Consumer Retailing Industry Average Movement	6.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de W8A ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de W8A (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1909	268,500	Tim Wentworth	www.walgreensbootsalliance.com

Walgreens Boots Alliance, Inc. opera como empresa de asistencia sanitaria, farmacia y venta al por menor en Estados Unidos, Reino Unido, Alemania e internacionalmente. Opera a través de tres segmentos: U.S. Retail Pharmacy, International y U.S.

Resumen de fundamentos de Walgreens Boots Alliance, Inc.

¿Cómo se comparan los beneficios e ingresos de Walgreens Boots Alliance con su capitalización de mercado?
Estadísticas fundamentales de W8A
Capitalización bursátil	€14.77b
Beneficios(TTM)	-€5.67b
Ingresos (TTM)	€135.73b

0.1x

Ratio precio-ventas (PS)

-2.6x

Ratio precio-beneficio (PE)

¿Está W8A sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de W8A
Ingresos	US$144.60b
Coste de los ingresos	US$117.72b
Beneficio bruto	US$26.88b
Otros gastos	US$32.91b
Beneficios	-US$6.04b

Últimos beneficios comunicados

Feb 29, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-7.00
Margen bruto	18.59%
Margen de beneficio neto	-4.18%
Ratio deuda/patrimonio	61.7%

¿Cómo se ha desempeñado W8A a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

5.5%

Rentabilidad actual por dividendo

-24%

Ratio de pagos

Resumen de acción W8A

Recompensas

Análisis de riesgos

Competidores de Walgreens Boots Alliance, Inc.

XTRA:RDC

€2.6b

XTRA:B4B

€1.8b

XTRA:HFG

€1.1b

BOVESPA:RADL3

R$43.6b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New major risk - Financial position

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

Upcoming dividend of US$0.25 per share at 4.4% yield

Recent updates

New major risk - Financial position

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

Upcoming dividend of US$0.25 per share at 4.4% yield

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

First quarter 2024 earnings released: US$0.078 loss per share (vs US$4.31 loss in 1Q 2023)

The Shareholder Commons, Inc Files a Notice of Exempt Solicitation to Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2023

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$3.57 loss per share (vs US$5.02 profit in FY 2022)

Walgreens Boots Alliance, Inc. Appoints Tim Wentworth as Chief Executive Officer, Effective October 23, 2023

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from S&P 100

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Walgreens Boots Alliance, Inc. Announces CEO Changes

Upcoming dividend of US$0.48 per share at 6.6% yield

High number of new directors

Walgreens Boots Alliance, Inc. Announces Departure of James Kehoe as Executive Vice President

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on September 12, 2023

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire 120 pharmacies in Texas, Louisiana and Arkansas from Brookshire Grocery Company.

Third quarter 2023 earnings released: EPS: US$0.14 (vs US$0.33 in 3Q 2022)

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Upcoming dividend of US$0.48 per share at 6.1% yield

CEO & Director recently bought €313k worth of stock

Second quarter 2023 earnings released: EPS: US$0.81 (vs US$1.02 in 2Q 2022)

Upcoming dividend of US$0.48 per share at 5.2% yield

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on March 10, 2023

Walgreens Reportedly Weighs $2 Billion Sale of Pharmacy Automation Unit

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

First quarter 2023 earnings released: US$4.31 loss per share (vs US$4.14 profit in 1Q 2022)

Walgreens Boots Alliance, Inc. to Report Q1, 2023 Results on Jan 05, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Independent Director recently sold €640k worth of stock

Upcoming dividend of US$0.48 per share

Walgreens Boots Alliance, Inc. Announces Resignation of William Foote, the Board Lead Independent Director

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2022

Full year 2022 earnings released: EPS: US$5.02 (vs US$2.31 in FY 2021)

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into a definitive agreement to acquire remaining 45% stake in CareCentrix, Inc. for approximately $390 million.

John Standley to Leave as Executive Vice President of Walgreens Boots Alliance, Inc. on November 1, 2022

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire additional 30% stake in Shields Specialty Pharmacy Holdings, LLC from Welsh, Carson, Anderson & Stowe, Jack Shields & others for approximately $1.4 billion.

Walgreens Boots Alliance, Inc. to Report Q4, 2022 Results on Oct 13, 2022

Walgreens Boots Alliance, Inc. Announces Executive Appointments

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. Names Alethia Jackson Senior Vice President, ESG and Chief DEI Officer

Walgreens Boots Alliance, Inc. Announces Resignation of David J. Brailer as Member of the Board of Directors

Upcoming dividend of US$0.48 per share

Jnd Legal Administration Announces A Class Action Lawsuit in the U.S. District Court for the District of Arizona Against Defendants Theranos, Inc., Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Company

Walgreens Boots Alliance Increases Quarterly Dividend, Payable September 9, 2022

Third quarter 2022 earnings released: EPS: US$0.33 (vs US$1.28 in 3Q 2021)

Walgreens Boots Alliance Concludes Strategic Review and Decides to Retain Ownership of Its Successful Boots Business